Appropriate implantable cardioverter-defibrillator interventions in cardiac resynchronization therapy-defibrillator (CRT-D) patients undergoing device replacement: time to downgrade from CRT-D to CRT-pacemaker? Insights from real-world clinical practice in the DECODE CRT-D analysis.
Cardiac Resynchronization Therapy With or Without Defibrillation: A Long-Standing Debate.
Golzio PG, Bocchino PP, Bissolino A, Angelini F, Gravinese C, Frea S.
Cardiol Rev. 2022 Sep-Oct 01;30(5):221-233. doi: 10.1097/CRD.0000000000000388. Epub 2021 Mar 19.
Cardiac resynchronization therapy (CRT) device replacement considerations: upgrade or downgrade? A complex decision in the current clinical setting.
Nakou ES, Simantirakis EN, Kallergis EM, Nakos KS, Vardas PE.
Europace. 2017 May 1;19(5):705-711. doi: 10.1093/europace/euw317.
Predictors and outcomes of cardiac resynchronization therapy extended to the second generator.
Li X, Yang D, Kusumoto F, Shen WK, Mulpuru S, Zhou S, Liang J, Wu G, Yang M, Liu JQ, Friedman PA, Cha YM.
Heart Rhythm. 2017 Dec;14(12):1793-1800. doi: 10.1016/j.hrthm.2017.09.002. Epub 2017 Sep 14.
Ampere Hour as a Predictor of Cardiac Resynchronization Defibrillator Pulse Generator Battery Longevity: A Multicenter Study.
Ellis CR, Dickerman DI, Orton JM, Hassan S, Good ED, Okabe T, Andriulli JA, Quan KJ, Greenspon AJ.
Pacing Clin Electrophysiol. 2016 Jul;39(7):658-68. doi: 10.1111/pace.12831. Epub 2016 Mar 11.
Battery longevity of implantable cardioverter-defibrillators and cardiac resynchronization therapy defibrillators: technical, clinical and economic aspects. An expert review paper from EHRA.
Boriani G, Merino J, Wright DJ, Gadler F, Schaer B, Landolina M.
Europace. 2018 Dec 1;20(12):1882-1897. doi: 10.1093/europace/euy066.
Management of functional Sprint Fidelis leads at cardiac resynchronization therapy-defibrillator generator replacement: a novel option for preventing inappropriate shocks from lead failure in fragile patients with high risk of sudden death.
Zhu DWX, Chu MM, House CM.
Europace. 2017 Dec 1;19(12):2007-2014. doi: 10.1093/europace/euw311.
Comparative Effectiveness of Cardiac Resynchronization Therapy Defibrillators Versus Standard Implantable Defibrillators in Medicare Patients.
Zusterzeel R, Caños DA, Sanders WE, Silverman H, MaCurdy TE, Worrall CM, Kelman J, Marinac-Dabic D, Strauss DG.
Am J Cardiol. 2015 Jul 1;116(1):79-84. doi: 10.1016/j.amjcard.2015.03.037. Epub 2015 Apr 8.
First Demonstration of Cardiac Resynchronization Therapy Defibrillator Service Life Exceeding Patient Survival in a Heart Failure with Reduced Ejection Fraction Cohort.
Williams JL, Harley B, Williams G.
J Innov Card Rhythm Manag. 2020 Dec 15;11(12):4325-4332. doi: 10.19102/icrm.2020.111203. eCollection 2020 Dec.
Cardiac resynchronization therapy improves myocardial conduction.
Yang M, Li X, Yang D, Li Y, Zhou S, Liang J, Wu G, Del-Carpio Munoz F, Chen HH, Friedman PA, Cha YM.
Pacing Clin Electrophysiol. 2019 Feb;42(2):238-246. doi: 10.1111/pace.13581. Epub 2018 Dec 27.
Economic impact of longer battery life of cardiac resynchronization therapy defibrillators in Sweden.
Gadler F, Ding Y, Verin N, Bergius M, Miller JD, Lenhart GM, Russell MW.
Clinicoecon Outcomes Res. 2016 Oct 31;8:657-666. doi: 10.2147/CEOR.S114921. eCollection 2016.
